Problems of Radiation Medicine and Radiobiology

O. O. Shumeiko¹,², L. O. Poluben¹, B. T. Klimuk¹, L. A. Rybchenko¹, L. V. Neumerzhitskaya¹,
R. M. Verbilenko¹, S. V. Frolov², S. V. Klymenko¹,²

¹State Institution «National Research Center for Radiation Medicine of the National Academy of Medical Sciences of Ukraine», 53 Melnykova str., Kyiv, 04050, Ukraine
²Bogomolets National Medical University, 13, Tarasa Shevchenko Blvd, Kyiv, 01601, Ukraine

EVALUATION OF BURDENSOME SYMPTOMS IN PATIENTS WITH RADIATION/ASSOCIATED AND SPONTANEOUS MYELOPROILIFERATIVE NEOPLASMS WITH THE USE OF OPTIMIZED SELF/ASSESSMENT MPN/SAF TSS

Objective. To investigate the intensity of burdensome symptoms using self-assessment MPN-SAF TSS in patients with radiation-associated and spontaneous myeloproiliferative neoplasms (MPNs).
Materials and methods. The study included 89 patients with radiation-associated and spontaneous MPNs, the burdensome symptoms of MPN were determined using MPN-SAF TSS.
Results. The average score for complaints in patients with radiation-associated MPNs was significantly higher than in patients with spontaneous MPNs – 43.46 and 25.04 points, respectively (p = 0.003). MPN patients classified by subtypes also showed differences regarding intensity of burdensome MPN symptoms, demonstrating significantly higher average score of complaints among primary myelofibrosis patients (35.60), compared to polycythemia vera (29.60) and essential thrombocythemia (18.05) patients, (p = 0.005). Our study did not reveal any influence of the JAK2 V617F mutation on MPN burdensome symptoms intensity in MPN patients.
Conclusions. We demonstrated a higher intensity of the MPN burdensome symptoms determined by the optimized self-assessment MPN-SAF TSS in patients with radiation-associated, and in primary myelofibrosis patients, indicating increased severity of patient’s general conditions at the stage of diagnosis verification. It is advisable to use the optimized MPN-SAF TSS at the moment of molecular genetic testing during the diagnosis of MPN for selection or modifying treatment strategies in order to achieve better quality of life for patients
Key words: Myeloproliferative neoplasms, ionizing radiation, MPN-SAF TSS, JAK2 V617F mutation.

Problems of radiation medicine and radiobiology.
2018;23:510–516. doi: 10.33145/2304-8336-2018-23-510-516.

full text

1. Mishcheniuk OY, Kostukevich OM, Dmytrenko IV, Sholoyko VV, Prokopenko IM, Martina ZV, Pilipenko GV, Klymenko SV Molecular characterization of Ph-negative myeloproliferative neoplasms in Ukraine. Exp Oncol. 2013;35(3):202-6.

2. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24:1128-38. doi: 10.1038/leu.2010.69.

3. Kong H, Liu Y, Luo S, Li Q, Wang Q. Frequency of calreticulin (CALR) mutation and its clinical prognostic significance in essential thrombocythemia and primary myelofibrosis: a meta-analysis. Intern Med. 2016;55(15):1977-84. doi: 10.2169/internalmedicine.55.6214.

4. Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68-76. doi: 10.1182/blood-2011-01-328955.

5. Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, et al. The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401-8. doi: 10.1182/blood-2011-01-328955.

6. Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, et al. Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098-103. doi: 10.1200/JCO.2012.42.3863.

7. Azevedo AP, Silva SN, Reichert A, Lima F, Junior E, Rueff J. Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population. Biomed Rep. 2017;7(4):370-6. doi: 10.3892/br.2017.977.

8. Ivanyi JL, Marton E, Plander M. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia]. Orv Hetil. 2011;152(45):1795-803. doi: 10.1556/OH.2011.29226. Hungarian.

9. Duletic AN, Dekanic A, Hadzisejdic I, Kusen I, Matusan-Ilijas K, Grohovac D, et al. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms. Coll Antropol. 2012 Sep;36(3):859-65.

10. Takata Y, Seki R, Kanajii T, Nohara M, Koteda S, Kawaguchi K, et al. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms. Kurume Med J. 2014;60(3-4):89-97.